Skip to main content
Journal Guides9 min readUpdated Jul 13, 2026

Blood Advances Submission Guide: Article Choice and Hematology Fit

A practical Blood Advances submission guide for article choice, hematology fit, evidence packaging, and current ASH author requirements.

By Manusights Editorial Team
Editorial processThe Manusights editorial team researches and maintains our Clinical Medicine & Public Health guides, drawing on what we see across thousands of pre-submission manuscript reviews.How we work

Readiness scan

Find out if this manuscript is ready to submit.

Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.

Check my readinessAnthropic Privacy Partner. Zero-retention manuscript processing.See example reports

Quick answer: Use this Blood Advances submission guide for a clinically, translationally, or experimentally useful hematology contribution that has a complete evidence path, even when the paper does not need Blood's flagship-priority framing. The official ASH guide sets article-type and submission rules. Before upload, decide whether the manuscript is a Regular Article or a genuinely focused Research Letter, then make the Key Points, visual abstract, data statement, and first figure tell the same hematology story.

Run a Blood Advances submission readiness check before opening eJournalPress.

For a flagship-priority decision, see the Blood submission guide. For field-level routes, see best hematology journals.

From our manuscript review practice

Blood Advances is not simply the lower-threshold Blood route. The preparation question is whether a focused hematology contribution has a complete evidence path, the right article type, and a data and visual package readers can inspect.

Blood Advances submission facts

Item
Current official guidance
Publisher
American Society of Hematology
Submission route
Online through eJournalPress
Regular Article
4,000-word main text, 250-word abstract, 120-character title, up to 7 figures, Key Points, visual abstract, and Data Sharing Statement
Research Letter
1,200 words, no abstract, 25 references, and up to 2 figures or tables
Supplemental data
Submit with the original manuscript so it can be peer reviewed
Title rule
Maximum 120 characters including spaces
Submission fee
Current page lists $75 for specified categories and automatic waiver for manuscripts cascading from Blood
Author guidance

The publisher owns the live author rules, fees, and portal workflow. This page is a preparation tool for the decision the portal cannot make: whether the contribution, article type, evidence display, and hematology reader are aligned.

Is Blood Advances the right hematology reader?

Submit If

  • the manuscript makes a useful hematology contribution with a defined disease, cell, therapeutic, diagnostic, transfusion, thrombosis, or care-pathway question
  • the central conclusion has the population, comparator, condition, outcome, and boundary needed for a reader to judge it
  • the contribution is complete at its actual scale, whether it is a full Regular Article or one focused Research Letter message
  • the first figure, Key Points, and visual abstract can state one evidence-backed implication without claiming flagship-level generality
  • data, supplemental methods, and disclosures are ready at original submission rather than deferred until revision

Think Twice If

  • the manuscript uses hematologic samples but the principal question belongs to general oncology, immunology, or a method-specific journal
  • a short format would hide the control, follow-up, clinical context, or molecular evidence that makes the result interpretable
  • the conclusion relies on a broad disease or treatment claim while the study is an unreplicated local observation
  • the evidence is solid but the natural reader needs a disease-specific specialty journal rather than broad hematology
  • the paper is framed as a fallback from Blood without clearly stating what the Blood Advances reader gains from it

The hematology evidence test

Claim
Evidence a reader should inspect
Fix before submission
A treatment changes an outcome
Patient or model definition, comparator, outcome timing, effect estimate, uncertainty, and safety context
Keep causal language inside the design
A mechanism explains a hematology result
Perturbation, relevant control, measurement, and link to disease or blood-cell consequence
Do not let correlation stand in for mechanism
A service or quality finding should travel
Care setting, implementation conditions, outcome, and transfer limit
Separate a local workflow from a general recommendation
A focused report is important
One novel message, decisive evidence, and a complete boundary
Use a Regular Article if the short form hides the necessary proof

This is a Manusights preparation artifact, not an ASH checklist. It aligns the manuscript's claim with the evidence that is visible to a hematology reader.

Choose the article type before cutting the manuscript

Article type
Better fit when
Pause when
Regular Article
The result needs a complete research sequence, a 250-word abstract, visual abstract, data statement, and up to seven figures
Several weak stories are competing instead of one coherent contribution
Research Letter
One basic or clinical hematology message is focused, novel or important, and complete within the short format
The result depends on more than two figures or tables, an abstract, or hidden supplemental evidence
Review or viewpoint
The manuscript synthesizes evidence or frames a topic suited to the applicable article category
New primary data is being forced into an opinion-led route

Build the package around the visible evidence

Package component
Pre-submission check
Title and Key Points
State the hematology question and supported consequence within the live title limit
Abstract or letter opening
Make the system, evidence, result, and boundary readable before interpretation
Visual abstract
Use it to clarify the central finding, not to add a broader claim than the manuscript supports
Figures and tables
Put the decisive comparison, condition, effect, and uncertainty in the main file
Data and supplements
Submit the supporting data and methods at original submission so they are available for peer review
Cover letter
Explain the hematology readership, article type, key evidence, and any required disclosures
Cascade status
If the manuscript cascades from Blood, verify the current transfer and fee instructions in the live portal

In our pre-submission review work: Blood Advances failure patterns

In our pre-submission review work, we test whether a Blood Advances draft makes its hematology contribution inspectable before a reader encounters a long supplement. These named failure patterns are not private ASH criteria. They are practical mismatches between the official article format and a manuscript's evidence path. The article-type guide explicitly distinguishes a complete focused Research Letter from a Regular Article, so choosing the route early helps authors preserve the proof that matters.

Blood Advances short format removes the decisive control

Keep the comparison that carries the conclusion. A Research Letter can be concise without being incomplete. If the control, disease context, or uncertainty sits only in supplementary files, use the fuller route or narrow the claim. Blood Advances readers should be able to identify what was compared and why the result matters from the visible evidence.

Check whether your Blood Advances article type preserves the decisive evidence

Blood Advances clinical implication outruns the cohort

State the patient and care boundary early. A real hematology observation can be useful without proving a universal treatment or service recommendation. Put the eligibility logic, setting, outcome timing, and transfer limit near the conclusion. This turns a promising local finding into an honest, reviewable contribution.

Check whether your Blood Advances conclusion matches the cohort and outcome

Blood Advances mechanism claim lacks a hematology consequence

Connect the molecular result to the blood question. A molecular, genomic, or cellular signal should change how the reader understands a hematologic disease, cell population, treatment, or process. State the relevant perturbation and control, then separate a measured consequence from a proposed explanation.

Check whether the mechanism claim has a visible hematology evidence path

Blood Advances visual abstract adds a second story

Use one visual message. The visual abstract should make the manuscript easier to inspect, not introduce an outcome, pathway, or clinical promise that the text cannot support. Make it agree with the Key Points and first figure, then remove any implication that depends on unshown data.

Readiness check

Run the scan against the requirements while they're in front of you.

See score, top issues, and journal-fit signals before you submit.

Check my readinessAnthropic Privacy Partner. Zero-retention manuscript processing.See example reports

Route the paper to the right venue

Route
Best center of gravity
Think twice when
Blood Advances
Complete, useful hematology evidence with a clear readership and article-scale fit
The contribution is only hematology-adjacent
Blood
Field-level hematology priority with a broader significance case
The paper is sound but does not need a flagship-priority claim
Disease-specific hematology journal
A focused disease, method, or technical audience
Broad hematology readers need the central result
Oncology, immunology, or methods journal
The primary question belongs outside hematology
Blood-cell samples are the only reason for the proposed destination

Final Blood Advances checklist

  • The live ASH article-type and submission pages were checked before upload.
  • The Regular Article or Research Letter choice matches the complete evidence available.
  • Title, Key Points, visual abstract, first figure, and conclusion make the same-sized claim.
  • The main file contains the control and comparison that readers need to judge the result.
  • Supplemental data and primary data sets are ready at original submission.
  • The cover letter explains why the paper serves a hematology reader.
  • Any Blood cascade details and fee treatment were verified in the current portal.

Run a final Blood Advances fit review before upload.

Frequently asked questions

Blood Advances publishes basic and clinical hematology research across categories including clinical trials and observations, gene therapy, health services and outcomes, hematopoiesis, malignancies, thrombosis, transfusion medicine, transplantation, and vascular biology.

The current ASH article-type table lists a 4,000-word main-text limit, 250-word abstract, 120-character title, up to 7 figures, Key Points, a visual abstract, and a Data Sharing Statement for a Regular Article. Confirm the live guide before submitting.

The official guide describes Research Letters as focused, novel or important basic or clinical hematology communications. It lists a 1,200-word limit, no abstract, 25 references, and up to 2 figures or tables.

The current submission page lists a nonrefundable $75 fee for Regular Articles, Exceptional Case Reports, Point-Counterpoint, and Review Articles, and says the fee is automatically waived for manuscripts cascading from Blood. Verify the live requirements before paying.

References

Sources

  1. Blood Advances Article Types
  2. Blood Advances Manuscript Submission
  3. Blood Advances Style Guide

Before you upload

Choose the next useful decision step first.

Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.

Use the scan once the manuscript and target journal are concrete enough to evaluate.

Anthropic Privacy Partner. Zero-retention manuscript processing.

Internal navigation

Where to go next